Feverfew: Choosing a Product and Dosing

Dried feverfew leaf and capsules
Dried feverfew leaf and capsules
Fresh feverfew leaves
Fresh feverfew leaves
Feverfew leaf extract tested for parthenolide
Feverfew leaf extract tested for parthenolide

With most supplements, choosing a product is a matter of price and taste. With feverfew it is arguably the whole question, because the difference between two bottles on the same shelf can be larger than the difference between the herb and a placebo.

That is not rhetoric. When pharmacy researchers bought commercial feverfew products and measured the parthenolide each one delivered at its own recommended daily dose, the range was 0.06 to 9.7 mg per day — a 160-fold difference (Nelson 2002). An earlier analysis using three independent methods found that some products sold as feverfew contained no detectable parthenolide at all (Heptinstall 1992).

So this page is the practical one. What the different forms are, what the numbers on a label mean, which numbers are useless, how the doses used in trials translate, how long to take it, and how to stop.

Table of Contents

  1. How Bad the Variability Actually Is
  2. The Forms of Feverfew
  3. Reading a Feverfew Label
  4. The Doses Actually Used in Trials
  5. Translating a Trial Dose to a Real Product
  6. Chewing Fresh Leaves: Mouth Ulcers and Uncontrolled Dose
  7. Storage, Shelf Life and Degradation
  8. How Long to Take It, and How to Judge
  9. Stopping and Post-Feverfew Syndrome
  10. Combination Products and Stacking
  11. What It Costs and How It Compares
  12. Cautions and Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

How Bad the Variability Actually Is

Three published analyses define the problem, and each deserves to be read in its own numbers.

Nelson 2002 — the 160-fold finding

Researchers bought commercial feverfew products and analysed them by high-performance liquid chromatography (HPLC) (Nelson 2002). What they found:

The 160-fold figure is the product of two multiplying problems: the herb varies in potency, and the labels recommend very different amounts of it. A consumer following instructions faithfully has no way to know which end of that range they are on.

Heptinstall 1992 — some products had none

An international team measured parthenolide by HPLC, nuclear magnetic resonance (NMR) spectroscopy, HPLC of a derivative, and a platelet bioassay. All four methods agreed with each other, so the numbers are trustworthy. Their findings (Heptinstall 1992):

Two further wrinkles worth knowing. Feverfew is occasionally misidentified: Tanacetum vulgare (tansy) and Anthemis or Matricaria species look broadly similar to a non-botanist, and tansy contains thujone, which is genuinely toxic. And because parthenolide degrades, the same bottle is not the same product a year later — a dermatology group re-analysing a feverfew cream after two years found no parthenolide remaining (Paulsen 2010).

Jin 2008 — label claims not met

A 2008 laboratory study measured parthenolide in several commercial feverfew extracts with a validated HPLC assay. “No commercial feverfew extracts tested contained the label claimed parthenolide,” and even different batches from the same manufacturer had significantly different parthenolide content (Jin 2008). A parthenolide figure on a label is therefore a claim, not a guarantee.

The Forms of Feverfew

FormWhat it isEvidence and notes
Supercritical CO2 extract (the type used in the Diener and Pfaffenrath trials)Extraction with pressurised carbon dioxide to a reproducible specification; no solvent residue, and the process is controllable batch to batchThe form with the best trial evidence. This is the extract type used in the Diener 2005 trial, which reported a small benefit
Standardised dried-leaf capsulesMilled leaf with a stated parthenolide percentage, usually 0.2–0.7%Closest to what the positive 1980s trials used, with the quality number the 1980s trials lacked
Unstandardised dried-leaf capsulesMilled leaf, weight on the label, no parthenolide figureA lottery. This is the category the 160-fold finding came from
Freeze-dried leafLeaf dried at low temperature, which better preserves heat-sensitive chemistryUsed in the 1985 trial. Plausible on chemistry grounds; still needs a parthenolide figure to be meaningful
Alcoholic extract / tinctureEthanol extraction, sold as liquid or dried onto a carrierThe one preparation with a clearly negative trial (De Weerdt 1996, 0.5 mg parthenolide/day). Not disqualifying, but not encouraging
Tea from dried leafHot water infusionParthenolide is poorly water-soluble, so a tea delivers little of it. A water extract does show some activity in the laboratory (Recinella 2020), but this is not what was tested clinically
Fresh leaves, chewedThe traditional method: two or three small leaves dailyThe route most associated with mouth ulcers, and the dose is completely uncontrolled
Sublingual combination productsFeverfew plus ginger, taken at the onset of an attackA different intervention with a different purpose — acute, not preventive, and not feverfew alone
Topical parthenolide-depleted extractSkincare ingredient with parthenolide deliberately removed to avoid sensitising skinA cosmetic ingredient, unrelated to migraine, designed to have the parthenolide removed. In a 2010 patch-test study, four of seven feverfew-allergic patients tested positive to one of two creams containing such an extract, with reactions linked to simultaneous positive reactions to parthenolide; the authors concluded such products “may elicit positive patch test reactions in feverfew-sensitive patients” (Paulsen 2010)

Reading a Feverfew Label

Six label elements, in order of how much they tell a reader.

Label elementWhat a good product statesRed flag
Parthenolide in milligrams“0.5 mg parthenolide per capsule” an absolute number you can multiply by the daily dose (a 2008 analysis found no commercial extract tested met its labelled parthenolide content)No parthenolide figure anywhere on the label
Parthenolide percentage“Standardised to 0.7% parthenolide” useful, but only alongside the capsule weight“Standardised extract” with no marker compound named
Species and plant partTanacetum parthenium, leaf or aerial parts“Feverfew” with no Latin binomial; “whole herb” (stalks and roots have little parthenolide)
Extract type“Supercritical CO2 extract” or “dried leaf powder” stated plainly“10:1 extract” alone. A ratio is not a dose and cannot be compared to anything
Third-party testingA named testing programme, with a certificate of analysis available on requestA “GMP” (good manufacturing practice) logo and nothing else
Expiry and batchA real expiry date and lot number — parthenolide degrades, so these matter more than usualNo date; bulk packaging bought years' worth at a time

The single most useful question: can you work out how many milligrams of parthenolide you will swallow per day? If the label does not let you calculate that, you cannot compare the product with any study, and you cannot compare it with the bottle you bought last year. That is the practical meaning of the 160-fold finding.

A worked example. A capsule of 380 mg dried leaf standardised to 0.5% parthenolide contains 380 × 0.005 = 1.9 mg parthenolide. Two capsules daily is 3.8 mg/day — near the top of what the Nelson survey found in real products, and well above the 0.5 mg/day used in the negative Dutch trial. Whether more is better is unproven, but at least you know where you stand.

The Doses Actually Used in Trials

These are the doses the trials used:

TrialPreparationDoseDurationResult
Diener 2005Supercritical CO2 extract6.25 mg three times daily (18.75 mg/day)16 weeks0.6 fewer attacks/month than placebo (P = 0.0456)
Pfaffenrath 2002Supercritical CO2 extract2.08, 6.25 or 18.75 mg three times daily12 weeksFailed overall; 6.25 mg three times daily (t.i.d.) best in a 49-patient subgroup
Murphy 1988Dried feverfew leafOne capsule daily4 months per arm, crossoverFewer, less severe attacks
Johnson 1985Freeze-dried leaf powderCapsules replacing habitual fresh-leaf useSeveral monthsPlacebo group deteriorated
De Weerdt 1996Dried alcoholic extractOne capsule daily, 0.5 mg parthenolide9 months, crossoverNo effect
Pattrick 1989 (arthritis)Dried chopped feverfew70–86 mg once daily6 weeksNo benefit in rheumatoid arthritis

The commonly quoted range of 50–150 mg of dried leaf per day is a fair summary of the dried-leaf studies. It is not a dose for a CO2 extract, where 18.75 mg per day was the effective amount — because that is concentrated material, not leaf.

A 2020 systematic review of 19 randomised, controlled trials of single herbs for migraine found that “findings on the efficacy of feverfew were mixed,” with “positive, albeit limited evidence for butterbur,” and noted that “the risk of bias was high for many studies” (Lopresti 2020).

Translating a Trial Dose to a Real Product

Three points from the trial record.

1. A milligram figure does not carry between preparations. 18.75 mg of the trial CO2 extract and 18.75 mg of dried leaf powder are not comparable in any way. Extracts concentrate; leaf does not. A number only means something against the form it was measured in.

2. A stated parthenolide figure is the only common currency, and labels have not always met it. It is the only figure that means the same thing across preparations, but a 2008 analysis found that no commercial feverfew extract tested contained the parthenolide its label claimed (Jin 2008). For orientation, the negative Dutch trial delivered 0.5 mg/day; commercial products in the Nelson survey delivered 0.06–9.7 mg/day; the phase I safety trial, in people with cancer, went to 4 mg/day with no significant toxicity and no maximum tolerated dose reached, and at doses up to 4 mg there was “not detectable concentration in the plasma” (detection limit 0.5 ng/mL) (Curry 2004).

3. On a product that states nothing useful, the label dose is arbitrary. It cannot be matched to any trial dose, and going above it on an unquantified product adds an unknown amount.

One more honest note. There is no established dose-response relationship for feverfew in humans. The one study designed to find one — Pfaffenrath 2002 — failed to demonstrate it in its main analysis. Higher parthenolide is not proven to be better. It is simply the only variable you can measure.

Chewing Fresh Leaves: Mouth Ulcers and Uncontrolled Dose

The traditional British method — two or three fresh leaves in a sandwich each morning — is how feverfew's modern reputation began, and it is the method most associated with mouth ulcers.

Capsules of dried leaf largely bypass the mouth-ulcer problem by not contacting the oral mucosa. Home-grown leaves that are dried and put into capsules avoid that mouth contact, but the dose is still unknown.

Storage, Shelf Life and Degradation

Parthenolide is chemically reactive, and reactive compounds do not last. The 1992 analysis found parthenolide levels fell during storage of powdered leaf material (Heptinstall 1992), and a feverfew cream re-analysed two years after purchase had no detectable parthenolide left (Paulsen 2010). Formulation work found that physical properties of commercial extracts relevant to product quality, such as moisture uptake and compactibility, “varied greatly with source” (Jin 2008).

What follows from this:

How Long to Take It, and How to Judge

Feverfew is a preventive. That dictates everything about the schedule.

The expectations the data support: the best trial produced 0.6 fewer attacks per month than placebo. If your realistic hope is “perhaps one fewer attack most months, possibly more if I turn out to be a responder,” feverfew may satisfy you. If your hope is to stop having migraines, it will not.

Stopping and Post-Feverfew Syndrome

This is the part people miss, and it is important enough to have its own name.

Long-term users who stopped suddenly have described rebound effects. Regular users who quit suddenly have described a withdrawal cluster — rebound headache often worse than baseline, anxiety, poor sleep, fatigue, and muscle and joint stiffness — known as post-feverfew syndrome. The first controlled trial documented exactly this: habitual users switched to placebo had significantly more frequent and severe headache, nausea and vomiting, with unpleasant effects emerging in the early months (Johnson 1985).

One consequence: rebound headache after stopping can look like proof that feverfew was working, when it is a withdrawal effect. Details are in Side Effects and Post-Feverfew Syndrome.

Combination Products and Stacking

Feverfew appears in a lot of blends. A few notes:

What It Costs and How It Compares

Feverfew is inexpensive. Basic dried-leaf capsules typically cost a few pounds or dollars a month; a standardised or CO2 extract is more, but rarely dramatically so. Against a documented net benefit of 0.6 attacks per month in the best trial, and an adverse-event rate no higher than placebo, it is a low-cost, well-tolerated preventive with a small expected effect, and that effect can only be judged with a product whose contents can be quantified.

Where it falls short: it does not replace evaluation of frequent or disabling migraine, or effective prescription prophylaxis; and an unquantified capsule bought purely on price is the version of feverfew most likely to be one of the products containing almost no parthenolide.

Cautions and Interactions

Key Research Papers

Every identifier was verified live against NCBI E-utilities before being written here.

Product quality, content and stability

  1. Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. American Journal of Health-System Pharmacy. 2002;59(16):1527–1531 — PubMed PMID: 12185827 — The 150-fold per-capsule and 160-fold daily-dose findings.
  2. Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew: estimation of commercial and authenticated feverfew products. Journal of Pharmacy and Pharmacology. 1992;44(5):391–395 — PubMed PMID: 1359053 — Some products had no detectable parthenolide; levels fell during storage.
  3. Jin P, Madieh S, Augsburger LL. Selected physical and chemical properties of feverfew (Tanacetum parthenium) extracts important for formulated product quality and performance. AAPS PharmSciTech. 2008;9(1):22–30. — PubMed PMID: 18446457 — No commercial extract tested contained its label-claimed parthenolide; batches from one manufacturer differed significantly.
  4. Paulsen E, Christensen LP, Fretté XC, Andersen KE. Patch test reactivity to feverfew-containing creams in feverfew-allergic patients. Contact Dermatitis. 2010;63(3):146–150 — PubMed PMID: 20690937 — Four of seven feverfew-allergic patients reacted to one of two creams with a parthenolide-depleted extract; parthenolide undetectable in that cream re-analysed about two years later.
  5. Recinella L, Chiavaroli A, di Giacomo V, Antolini MD, Acquaviva A, Leone S, Brunetti L, Menghini L, Ak G, Zengin G, Di Simone SC, Ferrante C, Orlando G. Anti-Inflammatory and Neuromodulatory Effects Induced by Tanacetum parthenium Water Extract: Results from In Silico, In Vitro and Ex Vivo Studies. Molecules. 2020;26(1):22 — PubMed PMID: 33374525 — Laboratory and isolated-tissue activity of a water extract.

The dosing trials

  1. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention. Cephalalgia. 2005;25(11):1031–1041. — PubMed PMID: 16232154
  2. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a dose-response study. Cephalalgia. 2002;22(7):523–532 — PubMed PMID: 12230594 — The dose-response study that did not demonstrate a dose response overall.
  3. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. The Lancet. 1988;2(8604):189–192. — PubMed PMID: 2899663
  4. De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225–230 — PubMed PMID: 23195074 — Alcoholic extract, 0.5 mg parthenolide/day, no effect.
  5. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal (Clinical Research Ed.). 1985;291(6495):569–573. — PubMed PMID: 3929876
  6. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews. 2015;4(4):CD002286 — PubMed PMID: 25892430 — Mouth ulcers and gastrointestinal complaints listed as the commonest adverse events.
  7. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Annals of the Rheumatic Diseases. 1989;48(7):547–549 — PubMed PMID: 2673080 — 41 women, 70–86 mg dried chopped feverfew daily for six weeks, no apparent benefit.
  8. Lopresti AL, Smith SJ, Drummond PD. Herbal treatments for migraine: A systematic review of randomised-controlled studies. Phytotherapy Research. 2020;34(10):2493–2517 — PubMed PMID: 32310327 — Feverfew findings mixed across 19 trials of single herbs.

Safety, tolerability and combinations

  1. Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs. 2004;22(3):299–305 — PubMed PMID: 15122077 — Up to 4 mg parthenolide daily was well tolerated with no dose-limiting toxicity; parthenolide was not detectable in plasma.
  2. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. The Lancet. 1985;1(8437):1071–1074. — PubMed PMID: 2860288
  3. Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. Journal of Pharmacy and Pharmacology. 1990;42(8):553–557 — PubMed PMID: 1981582
  4. Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. The Lancet. 1982;2(8301):776. — PubMed PMID: 6125851
  5. Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: is a full reproductive study warranted? Reproductive Toxicology. 2006;22(4):688–693. — PubMed PMID: 16781113
  6. Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic M) in the treatment of migraine. Headache. 2011;51(7):1078–1086. — PubMed PMID: 21631494
  7. Cady RK, Schreiber CP, Beach ME, Hart CC. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Medical Science Monitor. 2005;11(9):PI65–PI69 — PubMed PMID: 16127373 — Open-label.
  8. Shrivastava R, Pechadre JC, John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clinical Drug Investigation. 2006;26(5):287–296. — PubMed PMID: 17163262
  9. Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. Feverfew for migraine prophylaxis: a systematic review. Journal of Dietary Supplements. 2009;6(2):91–103. — PubMed PMID: 22435410

PubMed Topic Searches

  1. PubMed: Feverfew standardisation and parthenolide content
  2. PubMed: Herbal supplement quality and adulteration
  3. PubMed: Supercritical CO2 extraction of botanicals
  4. PubMed: Parthenolide stability and storage
  5. PubMed: Tansy, thujone and misidentification
  6. PubMed: Feverfew and anticoagulant interactions
  7. PubMed: Herbal medicines and perioperative bleeding
  8. PubMed: Headache diaries in prophylaxis trials

Connections


Back to Table of Contents